LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome
Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson's Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid invol...
Saved in:
| Published in | Molecular neurodegeneration Vol. 20; no. 1; pp. 89 - 34 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
06.08.2025
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson's Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid involved in glycosphingolipid (GSL) catabolism, in preclinical models and clinical subjects. However, how LRRK2 regulates BMP and its significance with respect to lysosomal dysfunction in PD are poorly defined.
Using a combination of genetic and pharmacological approaches to modulate LRRK2 kinase activity, we explored the mechanisms by which LRRK2 can regulate the levels of BMP and PD-relevant GSLs across cellular models, including iPSC-derived microglia, and in tissues and biofluids from mice using mass spectrometry. The impact of LRRK2 activity on various aspects of lysosomal function, including endolysosomal GCase activity, was assessed using live-cell imaging and lysosomal immunoprecipitation. We employed imaging mass-spectrometry and FACS-based methods to specifically examine how LRRK2 modulates BMP and GSL levels across different cell types and regions of the brain. To confirm the relevance of our findings to disease, we measured lysosomal biomarkers in urine and cerebrospinal fluid (CSF) from human subjects carrying variants in LRRK2 associated with PD risk and from subjects dosed with a LRRK2 kinase inhibitor.
Our data demonstrate that LRRK2 can employ distinct mechanisms to control intracellular BMP levels and modulate lysosomal homeostasis depending on the tissue examined. We show that LRRK2 deletion or inhibition lowers urine BMP levels by reducing the secretion of BMP-containing vesicles from kidney into urine. In other cell types such as microglia, LRRK2-mediated inhibition of β-glucocerebrosidase (GCase), a PD-linked enzyme involved in GSL catabolism, leads to lysosomal GSL accumulation and increases BMP levels as a compensatory response to restore lysosomal homeostasis. LRRK2 inhibition normalizes lysosomal function and reduces GSL levels in preclinical models and CSF from LRRK2-PD patients.
Our study highlights the therapeutic potential of LRRK2 kinase inhibition to improve PD-associated lysosomal dysfunction and supports the utility of GSLs as CSF-based biomarkers of LRRK2 activity.
This work includes results from the following phase 1b study in PD patients: ClinicalTrials.gov ID: NCT03710707; https://clinicaltrials.gov/study/NCT03710707?intr=dnl201&rank=2 . The date of registration was 10/18/2018. |
|---|---|
| AbstractList | Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson's Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid involved in glycosphingolipid (GSL) catabolism, in preclinical models and clinical subjects. However, how LRRK2 regulates BMP and its significance with respect to lysosomal dysfunction in PD are poorly defined. Using a combination of genetic and pharmacological approaches to modulate LRRK2 kinase activity, we explored the mechanisms by which LRRK2 can regulate the levels of BMP and PD-relevant GSLs across cellular models, including iPSC-derived microglia, and in tissues and biofluids from mice using mass spectrometry. The impact of LRRK2 activity on various aspects of lysosomal function, including endolysosomal GCase activity, was assessed using live-cell imaging and lysosomal immunoprecipitation. We employed imaging mass-spectrometry and FACS-based methods to specifically examine how LRRK2 modulates BMP and GSL levels across different cell types and regions of the brain. To confirm the relevance of our findings to disease, we measured lysosomal biomarkers in urine and cerebrospinal fluid (CSF) from human subjects carrying variants in LRRK2 associated with PD risk and from subjects dosed with a LRRK2 kinase inhibitor. Our data demonstrate that LRRK2 can employ distinct mechanisms to control intracellular BMP levels and modulate lysosomal homeostasis depending on the tissue examined. We show that LRRK2 deletion or inhibition lowers urine BMP levels by reducing the secretion of BMP-containing vesicles from kidney into urine. In other cell types such as microglia, LRRK2-mediated inhibition of [beta]-glucocerebrosidase (GCase), a PD-linked enzyme involved in GSL catabolism, leads to lysosomal GSL accumulation and increases BMP levels as a compensatory response to restore lysosomal homeostasis. LRRK2 inhibition normalizes lysosomal function and reduces GSL levels in preclinical models and CSF from LRRK2-PD patients. Our study highlights the therapeutic potential of LRRK2 kinase inhibition to improve PD-associated lysosomal dysfunction and supports the utility of GSLs as CSF-based biomarkers of LRRK2 activity. Abstract Background Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson’s Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid involved in glycosphingolipid (GSL) catabolism, in preclinical models and clinical subjects. However, how LRRK2 regulates BMP and its significance with respect to lysosomal dysfunction in PD are poorly defined. Methods Using a combination of genetic and pharmacological approaches to modulate LRRK2 kinase activity, we explored the mechanisms by which LRRK2 can regulate the levels of BMP and PD-relevant GSLs across cellular models, including iPSC-derived microglia, and in tissues and biofluids from mice using mass spectrometry. The impact of LRRK2 activity on various aspects of lysosomal function, including endolysosomal GCase activity, was assessed using live-cell imaging and lysosomal immunoprecipitation. We employed imaging mass-spectrometry and FACS-based methods to specifically examine how LRRK2 modulates BMP and GSL levels across different cell types and regions of the brain. To confirm the relevance of our findings to disease, we measured lysosomal biomarkers in urine and cerebrospinal fluid (CSF) from human subjects carrying variants in LRRK2 associated with PD risk and from subjects dosed with a LRRK2 kinase inhibitor. Results Our data demonstrate that LRRK2 can employ distinct mechanisms to control intracellular BMP levels and modulate lysosomal homeostasis depending on the tissue examined. We show that LRRK2 deletion or inhibition lowers urine BMP levels by reducing the secretion of BMP-containing vesicles from kidney into urine. In other cell types such as microglia, LRRK2-mediated inhibition of β-glucocerebrosidase (GCase), a PD-linked enzyme involved in GSL catabolism, leads to lysosomal GSL accumulation and increases BMP levels as a compensatory response to restore lysosomal homeostasis. LRRK2 inhibition normalizes lysosomal function and reduces GSL levels in preclinical models and CSF from LRRK2-PD patients. Conclusions Our study highlights the therapeutic potential of LRRK2 kinase inhibition to improve PD-associated lysosomal dysfunction and supports the utility of GSLs as CSF-based biomarkers of LRRK2 activity. Trial registration This work includes results from the following phase 1b study in PD patients: ClinicalTrials.gov ID: NCT03710707; https://clinicaltrials.gov/study/NCT03710707?intr=dnl201&rank=2 . The date of registration was 10/18/2018. Background Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson's Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid involved in glycosphingolipid (GSL) catabolism, in preclinical models and clinical subjects. However, how LRRK2 regulates BMP and its significance with respect to lysosomal dysfunction in PD are poorly defined. Methods Using a combination of genetic and pharmacological approaches to modulate LRRK2 kinase activity, we explored the mechanisms by which LRRK2 can regulate the levels of BMP and PD-relevant GSLs across cellular models, including iPSC-derived microglia, and in tissues and biofluids from mice using mass spectrometry. The impact of LRRK2 activity on various aspects of lysosomal function, including endolysosomal GCase activity, was assessed using live-cell imaging and lysosomal immunoprecipitation. We employed imaging mass-spectrometry and FACS-based methods to specifically examine how LRRK2 modulates BMP and GSL levels across different cell types and regions of the brain. To confirm the relevance of our findings to disease, we measured lysosomal biomarkers in urine and cerebrospinal fluid (CSF) from human subjects carrying variants in LRRK2 associated with PD risk and from subjects dosed with a LRRK2 kinase inhibitor. Results Our data demonstrate that LRRK2 can employ distinct mechanisms to control intracellular BMP levels and modulate lysosomal homeostasis depending on the tissue examined. We show that LRRK2 deletion or inhibition lowers urine BMP levels by reducing the secretion of BMP-containing vesicles from kidney into urine. In other cell types such as microglia, LRRK2-mediated inhibition of [beta]-glucocerebrosidase (GCase), a PD-linked enzyme involved in GSL catabolism, leads to lysosomal GSL accumulation and increases BMP levels as a compensatory response to restore lysosomal homeostasis. LRRK2 inhibition normalizes lysosomal function and reduces GSL levels in preclinical models and CSF from LRRK2-PD patients. Conclusions Our study highlights the therapeutic potential of LRRK2 kinase inhibition to improve PD-associated lysosomal dysfunction and supports the utility of GSLs as CSF-based biomarkers of LRRK2 activity. Trial registration This work includes results from the following phase 1b study in PD patients: ClinicalTrials.gov ID: NCT03710707; Keywords: LRRK2, Lysosome, Parkinson's disease, BMP and glycosphingolipids Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson's Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid involved in glycosphingolipid (GSL) catabolism, in preclinical models and clinical subjects. However, how LRRK2 regulates BMP and its significance with respect to lysosomal dysfunction in PD are poorly defined. Using a combination of genetic and pharmacological approaches to modulate LRRK2 kinase activity, we explored the mechanisms by which LRRK2 can regulate the levels of BMP and PD-relevant GSLs across cellular models, including iPSC-derived microglia, and in tissues and biofluids from mice using mass spectrometry. The impact of LRRK2 activity on various aspects of lysosomal function, including endolysosomal GCase activity, was assessed using live-cell imaging and lysosomal immunoprecipitation. We employed imaging mass-spectrometry and FACS-based methods to specifically examine how LRRK2 modulates BMP and GSL levels across different cell types and regions of the brain. To confirm the relevance of our findings to disease, we measured lysosomal biomarkers in urine and cerebrospinal fluid (CSF) from human subjects carrying variants in LRRK2 associated with PD risk and from subjects dosed with a LRRK2 kinase inhibitor. Our data demonstrate that LRRK2 can employ distinct mechanisms to control intracellular BMP levels and modulate lysosomal homeostasis depending on the tissue examined. We show that LRRK2 deletion or inhibition lowers urine BMP levels by reducing the secretion of BMP-containing vesicles from kidney into urine. In other cell types such as microglia, LRRK2-mediated inhibition of β-glucocerebrosidase (GCase), a PD-linked enzyme involved in GSL catabolism, leads to lysosomal GSL accumulation and increases BMP levels as a compensatory response to restore lysosomal homeostasis. LRRK2 inhibition normalizes lysosomal function and reduces GSL levels in preclinical models and CSF from LRRK2-PD patients. Our study highlights the therapeutic potential of LRRK2 kinase inhibition to improve PD-associated lysosomal dysfunction and supports the utility of GSLs as CSF-based biomarkers of LRRK2 activity. This work includes results from the following phase 1b study in PD patients: ClinicalTrials.gov ID: NCT03710707; https://clinicaltrials.gov/study/NCT03710707?intr=dnl201&rank=2 . The date of registration was 10/18/2018. Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson's Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid involved in glycosphingolipid (GSL) catabolism, in preclinical models and clinical subjects. However, how LRRK2 regulates BMP and its significance with respect to lysosomal dysfunction in PD are poorly defined.BACKGROUNDPathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson's Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid involved in glycosphingolipid (GSL) catabolism, in preclinical models and clinical subjects. However, how LRRK2 regulates BMP and its significance with respect to lysosomal dysfunction in PD are poorly defined.Using a combination of genetic and pharmacological approaches to modulate LRRK2 kinase activity, we explored the mechanisms by which LRRK2 can regulate the levels of BMP and PD-relevant GSLs across cellular models, including iPSC-derived microglia, and in tissues and biofluids from mice using mass spectrometry. The impact of LRRK2 activity on various aspects of lysosomal function, including endolysosomal GCase activity, was assessed using live-cell imaging and lysosomal immunoprecipitation. We employed imaging mass-spectrometry and FACS-based methods to specifically examine how LRRK2 modulates BMP and GSL levels across different cell types and regions of the brain. To confirm the relevance of our findings to disease, we measured lysosomal biomarkers in urine and cerebrospinal fluid (CSF) from human subjects carrying variants in LRRK2 associated with PD risk and from subjects dosed with a LRRK2 kinase inhibitor.METHODSUsing a combination of genetic and pharmacological approaches to modulate LRRK2 kinase activity, we explored the mechanisms by which LRRK2 can regulate the levels of BMP and PD-relevant GSLs across cellular models, including iPSC-derived microglia, and in tissues and biofluids from mice using mass spectrometry. The impact of LRRK2 activity on various aspects of lysosomal function, including endolysosomal GCase activity, was assessed using live-cell imaging and lysosomal immunoprecipitation. We employed imaging mass-spectrometry and FACS-based methods to specifically examine how LRRK2 modulates BMP and GSL levels across different cell types and regions of the brain. To confirm the relevance of our findings to disease, we measured lysosomal biomarkers in urine and cerebrospinal fluid (CSF) from human subjects carrying variants in LRRK2 associated with PD risk and from subjects dosed with a LRRK2 kinase inhibitor.Our data demonstrate that LRRK2 can employ distinct mechanisms to control intracellular BMP levels and modulate lysosomal homeostasis depending on the tissue examined. We show that LRRK2 deletion or inhibition lowers urine BMP levels by reducing the secretion of BMP-containing vesicles from kidney into urine. In other cell types such as microglia, LRRK2-mediated inhibition of β-glucocerebrosidase (GCase), a PD-linked enzyme involved in GSL catabolism, leads to lysosomal GSL accumulation and increases BMP levels as a compensatory response to restore lysosomal homeostasis. LRRK2 inhibition normalizes lysosomal function and reduces GSL levels in preclinical models and CSF from LRRK2-PD patients.RESULTSOur data demonstrate that LRRK2 can employ distinct mechanisms to control intracellular BMP levels and modulate lysosomal homeostasis depending on the tissue examined. We show that LRRK2 deletion or inhibition lowers urine BMP levels by reducing the secretion of BMP-containing vesicles from kidney into urine. In other cell types such as microglia, LRRK2-mediated inhibition of β-glucocerebrosidase (GCase), a PD-linked enzyme involved in GSL catabolism, leads to lysosomal GSL accumulation and increases BMP levels as a compensatory response to restore lysosomal homeostasis. LRRK2 inhibition normalizes lysosomal function and reduces GSL levels in preclinical models and CSF from LRRK2-PD patients.Our study highlights the therapeutic potential of LRRK2 kinase inhibition to improve PD-associated lysosomal dysfunction and supports the utility of GSLs as CSF-based biomarkers of LRRK2 activity.CONCLUSIONSOur study highlights the therapeutic potential of LRRK2 kinase inhibition to improve PD-associated lysosomal dysfunction and supports the utility of GSLs as CSF-based biomarkers of LRRK2 activity.This work includes results from the following phase 1b study in PD patients: ClinicalTrials.gov ID: NCT03710707; https://clinicaltrials.gov/study/NCT03710707?intr=dnl201&rank=2 . The date of registration was 10/18/2018.TRIAL REGISTRATIONThis work includes results from the following phase 1b study in PD patients: ClinicalTrials.gov ID: NCT03710707; https://clinicaltrials.gov/study/NCT03710707?intr=dnl201&rank=2 . The date of registration was 10/18/2018. |
| ArticleNumber | 89 |
| Audience | Academic |
| Author | Agam, Maayan Zhu, Sha Suh, Jung H. Davis, Sonnet S. Chen, John Di Paolo, Gilbert Huntwork-Rodriguez, Sarah Bondar, Vitaliy V. Davis, Oliver B. de Vicente, Javier Maciuca, Romeo Deen, Matthew C. Estrada, Anthony A Lewcock, Joseph W. Henry, Anastasia G. Maloney, Michael T. Nguyen, Hoang N. Astarita, Giuseppe Andrews, Shan V. Propson, Nicholas E. Ghosh, Rajarshi Arguello, Annie Wang, Xiang Chiu, Chi-Lu Caprioli, Richard M. Reyzer, Michelle L. Ho, Audrey Cheuk-Nga Masoud, Shababa T. Vocadlo, David J. |
| Author_xml | – sequence: 1 givenname: Michael T. surname: Maloney fullname: Maloney, Michael T. – sequence: 2 givenname: Xiang surname: Wang fullname: Wang, Xiang – sequence: 3 givenname: Rajarshi surname: Ghosh fullname: Ghosh, Rajarshi – sequence: 4 givenname: Shan V. surname: Andrews fullname: Andrews, Shan V. – sequence: 5 givenname: Romeo surname: Maciuca fullname: Maciuca, Romeo – sequence: 6 givenname: Shababa T. surname: Masoud fullname: Masoud, Shababa T. – sequence: 7 givenname: Maayan surname: Agam fullname: Agam, Maayan – sequence: 8 givenname: Richard M. surname: Caprioli fullname: Caprioli, Richard M. – sequence: 9 givenname: Giuseppe surname: Astarita fullname: Astarita, Giuseppe – sequence: 10 givenname: Vitaliy V. surname: Bondar fullname: Bondar, Vitaliy V. – sequence: 11 givenname: John surname: Chen fullname: Chen, John – sequence: 12 givenname: Chi-Lu surname: Chiu fullname: Chiu, Chi-Lu – sequence: 13 givenname: Sonnet S. surname: Davis fullname: Davis, Sonnet S. – sequence: 14 givenname: Audrey Cheuk-Nga surname: Ho fullname: Ho, Audrey Cheuk-Nga – sequence: 15 givenname: Hoang N. surname: Nguyen fullname: Nguyen, Hoang N. – sequence: 16 givenname: Nicholas E. surname: Propson fullname: Propson, Nicholas E. – sequence: 17 givenname: Michelle L. surname: Reyzer fullname: Reyzer, Michelle L. – sequence: 18 givenname: Oliver B. surname: Davis fullname: Davis, Oliver B. – sequence: 19 givenname: Matthew C. surname: Deen fullname: Deen, Matthew C. – sequence: 20 givenname: Sha surname: Zhu fullname: Zhu, Sha – sequence: 21 givenname: Gilbert surname: Di Paolo fullname: Di Paolo, Gilbert – sequence: 22 givenname: David J. surname: Vocadlo fullname: Vocadlo, David J. – sequence: 23 givenname: Anthony A surname: Estrada fullname: Estrada, Anthony A – sequence: 24 givenname: Javier surname: de Vicente fullname: de Vicente, Javier – sequence: 25 givenname: Joseph W. surname: Lewcock fullname: Lewcock, Joseph W. – sequence: 26 givenname: Annie surname: Arguello fullname: Arguello, Annie – sequence: 27 givenname: Jung H. surname: Suh fullname: Suh, Jung H. – sequence: 28 givenname: Sarah surname: Huntwork-Rodriguez fullname: Huntwork-Rodriguez, Sarah – sequence: 29 givenname: Anastasia G. orcidid: 0000-0002-8124-5477 surname: Henry fullname: Henry, Anastasia G. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40770658$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkt1qFDEUxwep2A99AS9kwBtvpp58TTJXUkrV4oJS7HXIJifb1JnJmswu7J2v4ev5JKadWroguUg455cfJ-R_XB2MccSqek3glBDVvs-EAeUNUNEAKAWNfFYdESmgIYy2B0_Oh9VxzrcAXAKIF9UhBymhFeqoul5cXX2h9Y8wmoy1sVPYhmlXJ1xtejNhrr-ZVJo5jn9-_c61CxkL2CTscWvGqe7DOrhcm6mebrDudznmOODL6rk3fcZXD_tJdf3x4vv552bx9dPl-dmisbzM0jBr_NK3Ai3vrFEelkwhaS0n4IXnFhVSRlBKIgvqyvydF0tnvfLMOaLYSXU5e100t3qdwmDSTkcT9H0hppU2aQq2R-0EEOVd5ylVnHE0SlIwnaLEsJY7WVwfZtd6sxzQWRynZPo96X5nDDd6FbeaUMYAOl4M7x4MKf7cYJ70ELLFvjcjxk3WjDLJBaEdKejbGV2ZMlsYfSxKe4frMyVAdYRSUajT_1BlORyCLWHwodT3Lrx5-obH4f_9dwHoDNgUc07oHxEC-i5Ueg6VLqHS96HSkv0Fo7m_BQ |
| Cites_doi | 10.1002/mds.29297 10.1038/s41467-017-02533-w 10.1186/s13024-019-0339-z 10.1093/brain/awt367 10.1038/nn.4534 10.1083/jcb.200911018 10.7554/eLife.87098 10.1016/j.heliyon.2020.e05191 10.1002/mds.26614 10.1038/s41593-020-00796-z 10.1016/j.arr.2016.05.001 10.1002/mds.27818 10.1016/S1474-4422(19)30320-5 10.1126/science.aan6298 10.1056/NEJMoa0901281 10.1212/WNL.0000000000010863 10.3389/fnins.2020.00865 10.1016/S1474-4422(24)00121-2 10.1146/annurev-biochem-092823-113814 10.1038/s41593-020-0650-6 10.1126/scitranslmed.abj2658 10.1002/ana.24781 10.1007/s00401-020-02181-3 10.1038/s41531-019-0076-6 10.1038/nature20414 10.1016/j.cub.2021.02.061 10.1038/s41598-018-33921-x 10.1016/j.chembiol.2014.06.008 10.1021/bi9002265 10.1523/JNEUROSCI.1920-10.2010 10.1038/s41588-024-01787-7 10.1038/s41598-021-91943-4 10.1194/jlr.R084343 10.1016/j.nbd.2009.05.023 10.1038/ng.3955 10.1038/nbt.3437 10.1126/scitranslmed.aav0820 10.3389/fnins.2020.00442 10.1021/acs.jproteome.8b00459 10.21203/rs.3.rs-2065993/v1] 10.1080/21541248.2016.1264352 10.1016/j.ymgme.2017.05.010 10.1001/jamanetworkopen.2021.5845 10.1194/jlr.E086173 10.1021/ac100818g 10.1093/brain/awx285 10.1074/jbc.R110.134452 10.1007/s00401-021-02325-z 10.7554/eLife.12813 10.1002/rcm.3444 10.1038/s41467-019-13413-w 10.1016/j.devcel.2020.11.016 10.1093/hmg/ddv314 10.1111/tra.12715 10.1111/febs.16099 10.1042/BST20180462 10.1002/mds.28549 10.1126/scitranslmed.abp8869 10.1371/journal.pone.0172348 10.1186/1471-2105-13-120 10.1126/scitranslmed.aar5429 10.1186/s13024-015-0010-2 10.1136/jmg.2004.024455 10.1073/pnas.1812196115 10.1186/s13742-015-0047-8 10.1126/scitranslmed.3004485 10.1073/pnas.2200553119 10.1016/j.nbd.2011.01.029 10.1007/s10719-021-10023-x 10.1007/BF01813904 10.1016/j.xcrm.2022.100661 10.1007/s11064-010-0337-6 10.1194/jlr.M057851 10.1126/sciadv.abb2454 10.3389/fnins.2020.00498 10.1042/BJ20071043 10.1038/s41531-022-00354-3 10.1038/nature15393 10.3390/ijms21218067 10.7554/eLife.87255 10.1093/brain/awv179 10.1093/hmg/ddab294 10.1126/science.aar5683 10.1016/j.nbd.2019.104626 10.1038/nm.4189 10.1016/j.cell.2021.08.002 10.1126/scitranslmed.aay1163 |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
| Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s13024-025-00880-7 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1750-1326 |
| EndPage | 34 |
| ExternalDocumentID | oai_doaj_org_article_d5018fd9f228434ea8720a9821a364d7 PMC12330094 A850891225 40770658 10_1186_s13024_025_00880_7 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR INH INR IPY ITC KQ8 LGEZI LOTEE M1P M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW ~8M CGR CUY CVF ECM EIF NPM 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c4047-3cafbf65ec49ca8f0b38e16c410f5f4ce8e231e77173cad0049f5bdcf8f3dd183 |
| IEDL.DBID | DOA |
| ISSN | 1750-1326 |
| IngestDate | Wed Aug 27 01:30:07 EDT 2025 Thu Aug 21 18:23:15 EDT 2025 Thu Aug 07 17:41:02 EDT 2025 Wed Aug 20 23:58:49 EDT 2025 Tue Aug 19 03:41:35 EDT 2025 Wed Aug 13 02:13:20 EDT 2025 Thu Aug 14 00:06:13 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | BMP and glycosphingolipids LRRK2 Parkinson’s disease Lysosome |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4047-3cafbf65ec49ca8f0b38e16c410f5f4ce8e231e77173cad0049f5bdcf8f3dd183 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-8124-5477 |
| OpenAccessLink | https://doaj.org/article/d5018fd9f228434ea8720a9821a364d7 |
| PMID | 40770658 |
| PQID | 3237451291 |
| PQPubID | 23479 |
| PageCount | 34 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d5018fd9f228434ea8720a9821a364d7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12330094 proquest_miscellaneous_3237451291 gale_infotracmisc_A850891225 gale_infotracacademiconefile_A850891225 pubmed_primary_40770658 crossref_primary_10_1186_s13024_025_00880_7 |
| PublicationCentury | 2000 |
| PublicationDate | 20250806 |
| PublicationDateYYYYMMDD | 2025-08-06 |
| PublicationDate_xml | – month: 8 year: 2025 text: 20250806 day: 6 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Molecular neurodegeneration |
| PublicationTitleAlternate | Mol Neurodegener |
| PublicationYear | 2025 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | E Sidransky (880_CR8) 2009; 361 880_CR46 EK Tan (880_CR18) 2010; 31 L Alvarez-Erviti (880_CR80) 2011; 42 H Pandya (880_CR44) 2017; 20 EK Gustavsson (880_CR66) 2024; 23 JC Ullman (880_CR56) 2020; 12 D Jennings (880_CR15) 2023; 38 MAS Baptista (880_CR53) 2020; 12 C Hsu (880_CR79) 2010; 189 BJ Andreone (880_CR41) 2020; 23 F Atashrazm (880_CR89) 2018; 8 AG Henry (880_CR27) 2015; 24 MA Nalls (880_CR4) 2019; 18 BM Schilder (880_CR65) 2022; 31 M Strohalm (880_CR38) 2008; 22 M Kedariti (880_CR62) 2022; 8 EM Rocha (880_CR87) 2020; 134 880_CR54 M Strohalm (880_CR39) 2010; 82 T Skotland (880_CR52) 2019; 60 HS Dhekne (880_CR74) 2023; 12 J Muffat (880_CR45) 2016; 22 RL Lieberman (880_CR76) 2009; 48 OB Davis (880_CR60) 2021; 56 M Karatas (880_CR75) 2020; 6 D Jennings (880_CR14) 2022; 14 HD Gallala (880_CR33) 2011; 36 A Abeliovich (880_CR1) 2016; 539 YL Tan (880_CR77) 2014; 21 AK Petersen (880_CR69) 2012; 13 RB Chan (880_CR9) 2017; 12 B Dehay (880_CR11) 2010; 30 L Bonet-Ponce (880_CR72) 2022; 289 O Karayel (880_CR13) 2022; 3 RN Alcalay (880_CR32) 2020; 35 E Eitan (880_CR81) 2016; 32 M Huebecker (880_CR12) 2019; 14 A Auton (880_CR37) 2015; 526 880_CR83 Y Chu (880_CR10) 2009; 35 D Chang (880_CR3) 2017; 49 RN Fuji (880_CR31) 2015; 7 EB Vitner (880_CR57) 2010; 285 DR Alessi (880_CR19) 2018; 360 880_CR68 S Bandres-Ciga (880_CR2) 2020; 140 JG Doench (880_CR42) 2016; 34 Y Fan (880_CR59) 2021; 142 X Wu (880_CR40) 2018; 17 D Ysselstein (880_CR63) 2019; 10 RG Langston (880_CR64) 2022; 14 HJ Rideout (880_CR70) 2020; 14 D Chiasserini (880_CR90) 2015; 10 H Iwaki (880_CR36) 2021; 36 O Goker-Alpan (880_CR6) 2004; 41 J Peter (880_CR82) 2008; 411 G Liu (880_CR91) 2016; 80 UN Medoh (880_CR30) 2024; 93 RN Alcalay (880_CR61) 2015; 138 AM Miranda (880_CR51) 2018; 9 M Abu-Remaileh (880_CR47) 2017; 358 PJ Hop (880_CR67) 2024; 56 GF Crotty (880_CR49) 2020; 95 880_CR71 880_CR73 X Wang (880_CR21) 2021; 11 L Bonet-Ponce (880_CR25) 2020; 6 J Gruenberg (880_CR29) 2020; 21 SR Guttikonda (880_CR43) 2021; 24 880_CR58 Z Sheng (880_CR20) 2012; 4 Z Akgoc (880_CR84) 2015; 56 RH Reynolds (880_CR5) 2019; 5 880_CR16 K-L Wallom (880_CR35) 2022; 39 X Wang (880_CR28) 2023; 12 LA Robak (880_CR7) 2017; 140 LK Hein (880_CR86) 2017; 121 GT Besley (880_CR85) 1986; 9 A Sanyal (880_CR88) 2020; 14 RA Ortega (880_CR93) 2021; 4 JH Kluss (880_CR17) 2019; 47 T Eguchi (880_CR26) 2018; 115 C Marras (880_CR50) 2016; 31 KE Murphy (880_CR92) 2014; 137 CA Boecker (880_CR24) 2021; 31 T Logan (880_CR34) 2021; 184 CC Chang (880_CR48) 2015; 4 L Blanc (880_CR78) 2018; 9 880_CR23 880_CR22 M Record (880_CR55) 2018; 59 |
| References_xml | – volume: 38 start-page: 386 year: 2023 ident: 880_CR15 publication-title: Mov Disord doi: 10.1002/mds.29297 – volume: 9 start-page: 291 year: 2018 ident: 880_CR51 publication-title: Nat Commun doi: 10.1038/s41467-017-02533-w – volume: 14 start-page: 40 year: 2019 ident: 880_CR12 publication-title: Mol Neurodegener doi: 10.1186/s13024-019-0339-z – ident: 880_CR22 – volume: 137 start-page: 834 year: 2014 ident: 880_CR92 publication-title: Brain doi: 10.1093/brain/awt367 – ident: 880_CR68 – volume: 20 start-page: 753 year: 2017 ident: 880_CR44 publication-title: Nat Neurosci doi: 10.1038/nn.4534 – volume: 189 start-page: 223 year: 2010 ident: 880_CR79 publication-title: J Cell Biol doi: 10.1083/jcb.200911018 – ident: 880_CR16 – volume: 12 start-page: e87098 year: 2023 ident: 880_CR74 publication-title: eLife doi: 10.7554/eLife.87098 – volume: 6 start-page: e05191 year: 2020 ident: 880_CR75 publication-title: Heliyon doi: 10.1016/j.heliyon.2020.e05191 – volume: 31 start-page: 1192 year: 2016 ident: 880_CR50 publication-title: Mov Disord doi: 10.1002/mds.26614 – volume: 24 start-page: 343 year: 2021 ident: 880_CR43 publication-title: Nat Neurosci doi: 10.1038/s41593-020-00796-z – volume: 32 start-page: 65 year: 2016 ident: 880_CR81 publication-title: Ageing Res Rev doi: 10.1016/j.arr.2016.05.001 – volume: 35 start-page: 134 year: 2020 ident: 880_CR32 publication-title: Mov Disord doi: 10.1002/mds.27818 – volume: 7 start-page: 273ra215 year: 2015 ident: 880_CR31 publication-title: Sci Transl Med – volume: 18 start-page: 1091 year: 2019 ident: 880_CR4 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(19)30320-5 – volume: 358 start-page: 807 year: 2017 ident: 880_CR47 publication-title: Science doi: 10.1126/science.aan6298 – volume: 361 start-page: 1651 year: 2009 ident: 880_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa0901281 – volume: 95 start-page: e3428 year: 2020 ident: 880_CR49 publication-title: Neurology doi: 10.1212/WNL.0000000000010863 – volume: 14 start-page: 865 year: 2020 ident: 880_CR70 publication-title: Front Neurosci doi: 10.3389/fnins.2020.00865 – volume: 23 start-page: 603 year: 2024 ident: 880_CR66 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(24)00121-2 – volume: 93 start-page: 447 year: 2024 ident: 880_CR30 publication-title: Annu Rev Biochem doi: 10.1146/annurev-biochem-092823-113814 – volume: 23 start-page: 927 year: 2020 ident: 880_CR41 publication-title: Nat Neurosci doi: 10.1038/s41593-020-0650-6 – volume: 14 start-page: eabj2658 year: 2022 ident: 880_CR14 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abj2658 – volume: 80 start-page: 674 year: 2016 ident: 880_CR91 publication-title: Ann Neurol doi: 10.1002/ana.24781 – volume: 140 start-page: 341 year: 2020 ident: 880_CR2 publication-title: Acta Neuropathol doi: 10.1007/s00401-020-02181-3 – volume: 5 start-page: 6 year: 2019 ident: 880_CR5 publication-title: Npj Parkinson’s Disease doi: 10.1038/s41531-019-0076-6 – volume: 539 start-page: 207 year: 2016 ident: 880_CR1 publication-title: Nature doi: 10.1038/nature20414 – volume: 31 start-page: 2140 year: 2021 ident: 880_CR24 publication-title: Curr Biol doi: 10.1016/j.cub.2021.02.061 – volume: 8 start-page: 15446 year: 2018 ident: 880_CR89 publication-title: Sci Rep doi: 10.1038/s41598-018-33921-x – volume: 21 start-page: 967 year: 2014 ident: 880_CR77 publication-title: Chem Biol doi: 10.1016/j.chembiol.2014.06.008 – volume: 48 start-page: 4816 year: 2009 ident: 880_CR76 publication-title: Biochemistry doi: 10.1021/bi9002265 – volume: 30 start-page: 12535 year: 2010 ident: 880_CR11 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.1920-10.2010 – volume: 56 start-page: 1371 year: 2024 ident: 880_CR67 publication-title: Nat Genet doi: 10.1038/s41588-024-01787-7 – volume: 11 start-page: 12900 year: 2021 ident: 880_CR21 publication-title: Sci Rep doi: 10.1038/s41598-021-91943-4 – volume: 60 start-page: 9 year: 2019 ident: 880_CR52 publication-title: J Lipid Res doi: 10.1194/jlr.R084343 – volume: 35 start-page: 385 year: 2009 ident: 880_CR10 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2009.05.023 – volume: 49 start-page: 1511 year: 2017 ident: 880_CR3 publication-title: Nat Genet doi: 10.1038/ng.3955 – volume: 34 start-page: 184 year: 2016 ident: 880_CR42 publication-title: Nat Biotechnol doi: 10.1038/nbt.3437 – volume: 12 start-page: eaav0820 year: 2020 ident: 880_CR53 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aav0820 – volume: 14 start-page: 442 year: 2020 ident: 880_CR88 publication-title: Front Neurosci doi: 10.3389/fnins.2020.00442 – volume: 17 start-page: 3308 year: 2018 ident: 880_CR40 publication-title: J Proteome Res doi: 10.1021/acs.jproteome.8b00459 – ident: 880_CR54 doi: 10.21203/rs.3.rs-2065993/v1] – volume: 9 start-page: 95 year: 2018 ident: 880_CR78 publication-title: Small GTPases doi: 10.1080/21541248.2016.1264352 – volume: 121 start-page: 259 year: 2017 ident: 880_CR86 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2017.05.010 – volume: 4 start-page: e215845 year: 2021 ident: 880_CR93 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2021.5845 – volume: 59 start-page: 1316 year: 2018 ident: 880_CR55 publication-title: J Lipid Res doi: 10.1194/jlr.E086173 – volume: 82 start-page: 4648 year: 2010 ident: 880_CR39 publication-title: Anal Chem doi: 10.1021/ac100818g – volume: 140 start-page: 3191 year: 2017 ident: 880_CR7 publication-title: Brain doi: 10.1093/brain/awx285 – volume: 285 start-page: 20423 year: 2010 ident: 880_CR57 publication-title: J Biol Chem doi: 10.1074/jbc.R110.134452 – volume: 142 start-page: 475 year: 2021 ident: 880_CR59 publication-title: Acta Neuropathol doi: 10.1007/s00401-021-02325-z – ident: 880_CR23 doi: 10.7554/eLife.12813 – volume: 22 start-page: 905 year: 2008 ident: 880_CR38 publication-title: Rapid Commun Mass Spectrom doi: 10.1002/rcm.3444 – volume: 10 start-page: 5570 year: 2019 ident: 880_CR63 publication-title: Nat Commun doi: 10.1038/s41467-019-13413-w – volume: 56 start-page: 260 year: 2021 ident: 880_CR60 publication-title: Dev Cell doi: 10.1016/j.devcel.2020.11.016 – volume: 24 start-page: 6013 year: 2015 ident: 880_CR27 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddv314 – volume: 21 start-page: 76 year: 2020 ident: 880_CR29 publication-title: Traffic doi: 10.1111/tra.12715 – volume: 289 start-page: 6871 year: 2022 ident: 880_CR72 publication-title: FEBS J doi: 10.1111/febs.16099 – volume: 47 start-page: 651 year: 2019 ident: 880_CR17 publication-title: Biochem Soc Trans doi: 10.1042/BST20180462 – volume: 36 start-page: 1795 year: 2021 ident: 880_CR36 publication-title: Genetic Resource Mov Disorders doi: 10.1002/mds.28549 – volume: 14 start-page: eabp8869 year: 2022 ident: 880_CR64 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abp8869 – volume: 12 start-page: e0172348 year: 2017 ident: 880_CR9 publication-title: PLoS ONE doi: 10.1371/journal.pone.0172348 – volume: 13 start-page: 120 year: 2012 ident: 880_CR69 publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-13-120 – ident: 880_CR71 doi: 10.1126/scitranslmed.aar5429 – volume: 10 start-page: 15 year: 2015 ident: 880_CR90 publication-title: Mol Neurodegener doi: 10.1186/s13024-015-0010-2 – volume: 41 start-page: 937 year: 2004 ident: 880_CR6 publication-title: J Med Genet doi: 10.1136/jmg.2004.024455 – volume: 115 start-page: E9115 year: 2018 ident: 880_CR26 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1812196115 – volume: 4 start-page: 7 year: 2015 ident: 880_CR48 publication-title: Gigascience doi: 10.1186/s13742-015-0047-8 – volume: 4 start-page: 164ra161 year: 2012 ident: 880_CR20 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3004485 – ident: 880_CR46 doi: 10.1073/pnas.2200553119 – volume: 42 start-page: 360 year: 2011 ident: 880_CR80 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2011.01.029 – volume: 39 start-page: 39 year: 2022 ident: 880_CR35 publication-title: Glycoconj J doi: 10.1007/s10719-021-10023-x – volume: 9 start-page: 59 year: 1986 ident: 880_CR85 publication-title: J Inherit Metab Dis doi: 10.1007/BF01813904 – volume: 3 start-page: 100661 year: 2022 ident: 880_CR13 publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2022.100661 – volume: 36 start-page: 1594 year: 2011 ident: 880_CR33 publication-title: Neurochem Res doi: 10.1007/s11064-010-0337-6 – volume: 56 start-page: 1006 year: 2015 ident: 880_CR84 publication-title: J Lipid Res doi: 10.1194/jlr.M057851 – volume: 6 start-page: eabb2454 year: 2020 ident: 880_CR25 publication-title: Sci Adv doi: 10.1126/sciadv.abb2454 – ident: 880_CR73 doi: 10.3389/fnins.2020.00498 – volume: 411 start-page: 71 year: 2008 ident: 880_CR82 publication-title: Biochem J doi: 10.1042/BJ20071043 – volume: 8 start-page: 92 year: 2022 ident: 880_CR62 publication-title: Npj Parkinson’s Disease doi: 10.1038/s41531-022-00354-3 – volume: 526 start-page: 68 year: 2015 ident: 880_CR37 publication-title: Nature doi: 10.1038/nature15393 – ident: 880_CR83 doi: 10.3390/ijms21218067 – volume: 12 start-page: e87255 year: 2023 ident: 880_CR28 publication-title: eLife doi: 10.7554/eLife.87255 – volume: 138 start-page: 2648 year: 2015 ident: 880_CR61 publication-title: Brain doi: 10.1093/brain/awv179 – volume: 31 start-page: 888 year: 2022 ident: 880_CR65 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddab294 – ident: 880_CR58 – volume: 360 start-page: 36 year: 2018 ident: 880_CR19 publication-title: Science doi: 10.1126/science.aar5683 – volume: 134 start-page: 104626 year: 2020 ident: 880_CR87 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2019.104626 – volume: 22 start-page: 1358 year: 2016 ident: 880_CR45 publication-title: Nat Med doi: 10.1038/nm.4189 – volume: 184 start-page: 4651 year: 2021 ident: 880_CR34 publication-title: Cell doi: 10.1016/j.cell.2021.08.002 – volume: 12 start-page: eaay1163 year: 2020 ident: 880_CR56 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aay1163 – volume: 31 start-page: 561 year: 2010 ident: 880_CR18 publication-title: Hum Mutat |
| SSID | ssj0047005 |
| Score | 2.4034204 |
| Snippet | Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for... Background Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic... Abstract Background Pathogenic variants in LRRK2 lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 89 |
| SubjectTerms | Animals BMP and glycosphingolipids Clinical Trials, Phase III as Topic Development and progression Female Genetic aspects Genetic variation Health aspects Humans Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - genetics Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - metabolism Lipid metabolism LRRK2 Lysophospholipids - metabolism Lysosome Lysosomes Lysosomes - metabolism Male Mice Mice, Inbred C57BL Microglia - metabolism Monoglycerides Multicenter Studies as Topic Neurological research Parkinson Disease - metabolism Parkinson's disease Protein kinases Randomized Controlled Trials as Topic |
| Title | LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40770658 https://www.proquest.com/docview/3237451291 https://pubmed.ncbi.nlm.nih.gov/PMC12330094 https://doaj.org/article/d5018fd9f228434ea8720a9821a364d7 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BuXBBhfKTUlZGQnBAUZPYSZxjilpVC1RoYaW9WY5_xIo2WzXbQ2-8Bq_HkzDjZKuNOPTSU6TYB2fG4_kmnvkG4B03InPWZbHHGDkWruKxzjO0Ky2lJUYpGbIJv54Vp3MxXeSLrVZflBPW0wP3gju0xDjnbeUzPEi5cFqWWaIrmaWaF8KGOnL0eZtgqj-DRYmba1MiI4vDjq7nREytW9HnySQuR24osPX_fyZvOaVxwuSWBzrZhScDdGR1v-Sn8MC1z2CvbjFsvrhh71lI5gx_yfdg_mU2-5yxX8sWvRSj4gXqEcGu-s7zrmNU7RwKv_7-_tOx4Zompg4qCK3X7Hx5ubQd02uGAJGd33SrbnXhnsP85PjHp9N46KAQG0EUDNxo3_gid0ZURkufNFy6tDAiTXzuhXHSIb5zJV3FG20pXPB5Y42XnluL1v4CdtpV614BQ-DFreap9lKIBs3Yea-1NY2RUiPMjODjRqDqsifKUCHAkIXqxa9Q_CqIX5URHJHMb2cSyXV4gapXg-rVXaqP4ANpTJEpolqMHioKcMFEaqVqieizSvHEiuBgNBNNyIyG3250rmiI8s5at7ruFM94KQgTpRG87PfA7ZoxFKY7YhmBHO2O0UeNR9rlz8DgjXCBU07n_n2I4TU8zsLOlnFSHMDO-uravUGktG4m8LBclBN4VNfT71N8Hh2ffZtNgqn8A0ivFIs |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LRRK2+kinase+activity+regulates+Parkinson%E2%80%99s+disease-relevant+lipids+at+the+lysosome&rft.jtitle=Molecular+neurodegeneration&rft.au=Maloney%2C+Michael+T.&rft.au=Wang%2C+Xiang&rft.au=Ghosh%2C+Rajarshi&rft.au=Andrews%2C+Shan+V.&rft.date=2025-08-06&rft.issn=1750-1326&rft.eissn=1750-1326&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs13024-025-00880-7&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13024_025_00880_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon |